First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments
Related Posts
Hecht JR, Oberoi A, Garralda Cabanas E, Jae Chon H, Digklia A, Rottey S, Martin Jimenez M, Chaney M, Hippenmeyer J, Lawrence T, Liu K,[...]
Duggirala N, Zhang S, Master A, Rao R, Kapoor NS, Bardia A, Lipsyc-Sharf M. Biology, care, and outcomes of gestational breast cancers: a review. Breast[...]
Yoo C, Ueno M, Klümpen HJ, Kelley RK, Vogel A, Furuse J, Ren Z, Yau T, Chan SL, Ozaka M, Oh SC, Gu S, Park[...]